Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SK pseudogene 231 (RN7SKP231) is a non-coding pseudogene related to the 7SK small nuclear RNA (RN7SK), a well-studied RNA involved in the regulation of RNA polymerase II transcription elongation through sequestration of the positive transcription elongation factor b (P-TEFb)[3][1][2]. RN7SKP231 itself does not produce functional RNA or protein; it is an inactive segment within the genome, believed to have arisen from duplication or retrotransposition events. There is no evidence suggesting RN7SKP231 has a role as a therapeutic target, nor does it have established biological or disease relevance. Clarification: - The entry “RN7SK pseudogene 231” is not a functional gene, protein, nor a direct therapeutic target. All molecular, functional, and disease associations described in the literature pertain to the functional RN7SK snRNA—not the pseudogene[2][1][3]. If you are interested in the functional RN7SK snRNA, it is a bona fide regulator of transcription elongation and cell differentiation and is linked to diseases when dysregulated, but this does not extend to pseudogenes. Summary of Core Points: - RN7SKP231 is a pseudogene. - It is not a therapeutic target or functional molecule. - No drugs, mechanisms, functions, or disease roles are attributed to it. - The actual 7SK RNA is a non-coding RNA involved in regulation of transcription, but RN7SKP231 is not active in these processes.
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RN7SK pseudogene 231 (RN7SKP231).